has made a name for itself in the list of top suppliers of Iron & Steel in India
Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review
Somatostatin secretion is perturbed in animal models of diabetes mellitus, which might explain the loss of appropriate hypoglycaemia-induced glucagon secretion, a defect that could be mitigated by somatostatin receptor 2 antagonists
Why this launch is important: Weekly therapy starting from 325 setting a new affordability benchmark Available in multi-dose vials & pre-filled pens for flexible treatment Approved by CDSCO based on Phase III clinical study in India Designed to improve access, adherence & long-term outcomes Supported by patient program Sankalp for better therapy initiation This launch comes at a time when India is entering a new era of semaglutide accessibility, driven by patent expiry and increasing competition among pharma leaders
Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, et al
In addition to BMI, semaglutide treatment was also associated with reduced total cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein cholesterol, triglycerides, alanine aminotransferase (ALT), and glycated hemoglobin levels as compared to the placebo
